A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).

NCT05156229 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class

Stopped PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety profile. Proceeding to Phase II did not require additional data from this Phase I Dose-Finding study.

Conditions

Interventions

Sponsor

Codiak BioSciences